• Facebook
  • X
  • Instagram
  • Contact Us
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Under-the-skin Velcade Found to Work Better in Farydak Triple Combo

by MM360 Staff | Jun 10, 2021 | Uncategorized

Using an under-the-skin formulation of Velcade (bortezomib), in combination with Farydak (panobinostat) and oral dexamethasone, leads to a better safety profile in people with relapsed or refractory (resistant) multiple myeloma than does the therapy’s original...

Phase 3 Trial of ATG-010 (Xpovio) for Advanced Myeloma Opens in China

by MM360 Staff | Jun 10, 2021 | Uncategorized

China’s regulatory agency has approved the start of a Phase 3 clinical trial testing ATG-010 (selinexor), in combination with Velcade (bortezomib) and dexamethasone, in multiple myeloma patients after one to three prior lines of treatment. The trial will include about...

EMA Plans Speedy Review of Cilta-cel, CAR T-cell Therapy for Advanced Myeloma

by MM360 Staff | Jun 10, 2021 | Uncategorized

An accelerated review will be given an application for European Union approval of ciltacabtagene autoleucel (cilta-cel), a potential CAR T-cell therapy for heavily pre-treated multiple myeloma patients, its developer, Janssen, announced. An accelerated assessment,...

EU Committee Supports Nexpovio for Heavily Treated Myeloma Patients

by MM360 Staff | Jun 10, 2021 | Uncategorized

A combination of Nexpovio (selinexor) and the corticosteroid dexamethasone has been recommended for conditional approval in the European Union to treat adults with relapsed or refractory multiple myeloma who received at least four prior therapies. This includes...

Cutting-Edge Test Detects Early Tumor Recurrence In Some Cancers

by MM360 Staff | Jun 10, 2021 | Uncategorized

(ABC News/Good Morning America) June 10, 2021 – A new blood test seeks to change the game in cancer management.
« Older Entries
Next Entries »

Recent Content

  • Belantamab Mafodotin Achieves Secondary End Point for Treatment of Relapsed, Refractory Multiple Myeloma
  • Efficacy and safety of daratumumab for the treatment of refractory/relapsed multiple myeloma. A systematic review of meta-analyses
  • Cell surface marker heterogeneity in human myeloma cell lines for modeling of disease and therapy
  • A systematic review on the epidemiology and treatment options of multiple Myeloma in Asia
  • Blenrep-Based Combo Provides Survival Benefit in Relapsed/Refractory Multiple Myeloma
  • A systematic literature review on clonal evolution events preceding relapse in multiple myeloma
  • Efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: a systematic review and meta-analysis
  • A systematic review and meta-analysis of carfilzomib-associated thrombocytopenia as an adverse event in patients with multiple myeloma
  • Comparing stem cell mobilization with chemotherapy and cytokine (G-CSF) versus cytokine alone in myeloma patients (MOCCCA): a randomized phase II, open-label, non-inferiority trial
  • Triplet regimen extends OS in relapsed or refractory multiple myeloma
  • Contact Us
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT